Vizora日本語

Kobayashi PharmaceuticalKOBAYASHI PHARMACEUTICAL CO.,LTD.4967東証プライム化学FY ending Dec 2025, consolidated, J-GAAP

Kobayashi Pharmaceutical FY ending Dec 2022 results

About 72% of Kobayashi Pharmaceutical's sales come from Domestic Business, with International Business and Direct Marketing Business making up much of the rest.

Out of every ¥100 of sales, about ¥16 is left as operating profit.

Revenue changed +7.1% from the prior year, operating profit +2.3%.

Revenue and profit pattern

Revenue and profit upRevenue grew faster

Revenue +7.1% · profit +2.3%, calculated from disclosed figures.

Operating leverage: 0.33× (profit growth ÷ revenue growth)

What changed from last year

FY ending Dec 2021 → FY ending Dec 2022

Revenue
+7.1%¥155.3B → ¥166.3B
Gross profit
+4.0%¥88.8B → ¥92.3B
Operating income
+2.3%¥26.1B → ¥26.7B
Net income attributable to owners
+1.6%¥19.7B → ¥20B
Operating cash flow
+42.4%¥22.4B → ¥31.9B
Free cash flow
-14.0%¥18.2B → ¥15.7B

Where the money goes

FY ending Dec 2021 → FY ending Dec 2022

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Kobayashi Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Dec 2022
Cost of sales
¥44
SG&A
¥40
Operating profit
¥16
Net profit kept
¥12

Annual margin trends

Gross margin55.5%
FY ending Dec 2019: 57.5%57.5%FY ending Dec 2020: 56.6%56.6%FY ending Dec 2021: 57.2%57.2%FY ending Dec 2022: 55.5%55.5%FY19FY20FY21FY22
Operating margin16.0%
FY ending Dec 2019: 16.2%16.2%FY ending Dec 2020: 17.2%17.2%FY ending Dec 2021: 16.8%16.8%FY ending Dec 2022: 16.0%16.0%FY19FY20FY21FY22
Net margin12.0%
FY ending Dec 2019: 12.1%12.1%FY ending Dec 2020: 12.8%12.8%FY ending Dec 2021: 12.7%12.7%FY ending Dec 2022: 12.0%12.0%FY19FY20FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2022

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第108期(2025/01/01－2025/12/31)

    ID S100XSXS2026-03-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第107期(2024/01/01－2024/12/31)

    ID S100VIKQ2025-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第106期(2023/01/01－2023/12/31)

    ID S100T3KX2024-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第105期(2022/01/01－2022/12/31)

    ID S100QGIS2023-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第104期(令和3年1月1日－令和3年12月31日)

    ID S100NR6F2022-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第103期(令和2年1月1日－令和2年12月31日)

    ID S100L0OB2021-03-26Open

Extracted from XBRL: 52 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image